Trial Profile
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Gemcitabine
- Indications Cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Cornerstone Pharmaceuticals Inc
- 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
- 19 Mar 2017 Status changed from suspended to discontinued.
- 06 Jan 2017 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017.